13 Aug 2020
Executive Interview – Richard Barfield, CFO

In this interview, Ergomed’s CFO Richard Barfield runs through:

  • The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m.
  • How Ergomed has demonstrated significant resilience through the COVID-19 crisis.
  • Some of the reasons behind the startling growth in Ergomed’s revenues over the last three years and how it intends to maintain that momentum.
  • An overview of Ergomed’s M&A strategy.
  • The outlook towards upcoming newsflow.

Ergomed is a global full-service CRO business with a core focus on the US and EU. It provides Phase I–III clinical services in addition to post-marketing pharmacovigilance (Phase IV) services through its PrimeVigilance division. The company is predominantly focused on oncology, orphan drugs, rare diseases and pharmacovigilance.